Travere Therapeutics Stock

Travere Therapeutics Dividend 2024

Travere Therapeutics Dividend

0 USD

Travere Therapeutics Dividend yield

Ticker

TVTX

ISIN

US89422G1076

WKN

A2QHYP

How much dividend does Travere Therapeutics 2024 pay?

According to the latest status from September 2024, Travere Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Travere Therapeutics price of 12.24 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Travere Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Travere Therapeutics Dividend Safe?

Travere Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, Travere Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Travere Therapeutics's Dividend Distributions

Travere Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Travere Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Travere Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Travere Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Travere Therapeutics Aktienanalyse

What does Travere Therapeutics do?

Travere Therapeutics, Inc is a pharmaceutical company specializing in rare diseases. It was founded in 2019 and is headquartered in San Diego, California. Travere is tirelessly working to develop innovative therapies to improve the lives of patients with rare diseases. History Travere Therapeutics was formed from the merger of Retrophin, Inc and privately held company Censa Pharmaceuticals, Inc. Retrophin was founded in 2011 by Martin Shkreli and had difficulties in developing therapies for rare diseases. Shkreli later left the company and Retrophin focused on developing therapies for multiple rare diseases. In 2019, Retrophin merged with Censa Pharmaceuticals to form Travere Therapeutics, a company solely dedicated to rare diseases. Business Model Travere Therapeutics' business model is to develop innovative therapies for rare diseases that address an unmet medical need. With a strong focus on research and development, the company is working to discover, develop, and market new and life-changing therapies. Travere Therapeutics has a strong pipeline of drugs and medications in various stages of clinical development. This pipeline includes therapies for rare diseases such as nephrotic syndromes, mucopolysaccharidosis, lipid disorders, and others. Divisions Travere Therapeutics specializes in two business areas: pharmaceuticals and diagnostics. Pharmaceutical Business Travere Therapeutics' pharmaceutical business includes researching, developing, and marketing therapies for rare diseases. The company has a strong focus on research and development and has a pipeline of drugs and therapies aimed at improving the lives of patients with rare diseases. Diagnostics Business Travere Therapeutics' diagnostics business focuses on diagnostic tests for rare diseases. The company has partnerships with labs and facilities around the world specializing in diagnostics and genetics to ensure accurate diagnosis of patients with rare diseases. Products Travere Therapeutics offers a variety of products and therapies in different stages of development. Here are some of the key products the company offers: · Isturisa: a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of the hormone cortisol. · Re-PLAI: a medication for the treatment of nephrotic syndromes, a group of disorders caused by kidney dysfunction. · Enzyme Replacement Therapy (ERT): an approach to treating inherited metabolic disorders by administering missing enzymes. Conclusion Travere Therapeutics is an innovative company specializing in developing therapies for rare diseases. The company has a strong pipeline of drugs and the expertise to develop therapies for patients who are underserved by traditional medications. With a focus on research and diagnostics, the company has the potential to improve the lives of millions of patients with rare diseases. Travere Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Travere Therapeutics stock

How much dividend does Travere Therapeutics pay?

Over the past 12 months, Travere Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Travere Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Travere Therapeutics?

The current dividend yield of Travere Therapeutics is .

When does Travere Therapeutics pay dividends?

Travere Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Travere Therapeutics?

Travere Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Travere Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Travere Therapeutics located?

Travere Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Travere Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Travere Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Travere Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Travere Therapeutics in the year 2023?

In the year 2023, Travere Therapeutics distributed 0 USD as dividends.

In which currency does Travere Therapeutics pay out the dividend?

The dividends of Travere Therapeutics are distributed in USD.

Andere Kennzahlen von Travere Therapeutics

Our stock analysis for Travere Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Travere Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.